OncoMatch/Clinical Trials/NCT06183489
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Is NCT06183489 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Elranatamab for smoldering multiple myeloma.
Treatment: Elranatamab — This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy for multiple myeloma
Previous therapy with any systemic therapy for multiple myeloma
Cannot have received: plasmapheresis
Exception: within 14 days of eligibility confirmation
Subject has had plasmapheresis within 14 days of elegibility confirmation
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0 x 10^9/L (≥1000/μL); Platelet count ≥75 x 10^9/L
Kidney function
Liver function
AST ≤2.5 x ULN; ALT ≤2.5 x ULN; total bilirubin ≤1.5 x ULN (except congenital bilirubinemia, then direct bilirubin ≤2.0 x ULN)
Absolute neutrophil count ≥1.0 x 10^9/L (ie, ≥1000/μL); Platelet count ≥75 x 10^9/L; AST ≤2.5 x ULN; ALT ≤2.5 x ULN; Total bilirubin ≤1.5 x ULN, except in subjects with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤2.0 x ULN is required)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify